Evidence map›Paper›PMID 23219592›Full record

ArticleToxicology2013

Exposure profiling of reactive compounds in complex mixtures.

Shilpi Goel, Julie A Evans-Johnson, Nadia I Georgieva, Gunnar Boysen

Open access · greenAbstract read
In one paragraph

Article in Toxicology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. The oral microbiome in autoimmune diseases: friend or foe?Journal of translational medicine · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Shilpi Goel *Department of Environmental and Occupational Health, The Winthrop P. Rockefeller Cancer Institute at The University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Julie A Evans-Johnson *Department of Environmental and Occupational Health, The Winthrop P. Rockefeller Cancer Institute at The University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Nadia I GeorgievaDepartment of Environmental and Occupational Health, The Winthrop P. Rockefeller Cancer Institute at The University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Gunnar BoysenDepartment of Environmental and Occupational Health, The Winthrop P. Rockefeller Cancer Institute at The University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Winthrop Rockefeller Foundation · USUniversity of Arkansas for Medical Sciences · US

Funding

Effects of Genetic Diversity on Carcinogen MetabolismR21ES023046 · NIEHS · UNIV OF ARKANSAS FOR MED SCIS · PI BOYSEN, GUNNAR · 2014 to 2015
$425k
A novel approach for quantitation of N-terminal valine adductsR21ES019684 · NIEHS · UNIV OF ARKANSAS FOR MED SCIS · PI BOYSEN, GUNNAR · 2011 to 2012
$405k
NIEHS NIH HHS R21 ES019684NIEHS NIH HHS R21 ES023046
6 · The paper itself

Abstract

Humans are constantly exposed to mixtures, such as tobacco smoke, exhaust from diesel, gasoline or new bio-fuels, containing several 1000 compounds, including many known human carcinogens. Covalent binding of reactive compounds or their metabolites to DNA and formation of stable adducts is believed to be the causal link between exposure and carcinogenesis. DNA and protein adducts are well established biomarkers for the internal dose of reactive compounds or their metabolites and are an integral part of science-based risk assessment. However, technical limitations have prevented comprehensive detection of a broad spectrum of adducts simultaneously. Therefore, most studies have focused on measurement of abundant individual adducts. These studies have produced valuable insight into the metabolism of individual carcinogens, but they are insufficient for risk assessment of exposure to complex mixtures. To overcome this limitation, we present herein proof-of-principle for comprehensive exposure assessment, using N-terminal valine adduct profiles as a biomarker. The reported method is based on our previously established immunoaffinity liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with modification to enrich all N-terminal valine alkylated peptides. The method was evaluated using alkylated peptide standards and globin reacted in vitro with alkylating agents (1,2-epoxy-3-butene, 1,2:3,4-diepoxybutane, propylene oxide, styrene oxide, N-ethyl-N-nitrosourea and methyl methanesulfonate), known to form N-terminal valine adducts. To demonstrate proof-of-principle, the method was successfully applied to globin from mice treated with four model compounds. The results suggest that this novel approach might be suitable for in vivo biomonitoring.

Indexed as

AnimalsBiomarkersCarcinogens, EnvironmentalChromatography, LiquidComplex MixturesEnvironmental ExposureFemaleHemoglobinsHumansMiceMice, Inbred C57BLTandem Mass SpectrometryValineBiomarkersCarcinogens, EnvironmentalComplex MixturesHemoglobinsValine1,2:3,4-diepoxybutane1,2 epoxy-3-butene1,3-butadiene1-hydroxy (or 2-hydroxy)-propyl-valine1-phenyl-2-hydroxyethyl-valine or 2-phenyl-2-hydroxyethyl-valine2,3,4-trihydroxybutyl-valine3,4-epoxy-1,2-butanediolBDBiomarkersBiomonitoringcarbamoylated-valineDEBEBEB-diolENUENU-Valethyl-valineEt-ValFAformic acidH(2)N-ValHbHB-ValhemoglobinHP-ValIAimmunoaffinityLC–MS/MSliquid chromatography–tandem mass spectrometrymethyl-methanesulfonatemethyl-valineMe-ValMixturesMMSMultiple exposure detectionN-(2-hydroxy-3-buten-1-yl)-valineN-ethyl-N-nitrosoureaN,N-(2,3-dihydroxy-1,4-butadiyl)-valinenon-alkylated-valineN-terminal valine adductsPOpropylene oxidepyr-ValSOSO-Valstyrene oxideTHB-Val

Identifiers

PMID23219592
PMCPMC4868061
OpenAlexW2043990962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.